filmov
tv
Optimal ADT for Patients With Prostate Cancer and CV History
Показать описание
Importance of optimal duration of ADT in patients with previous cardiovascular history to ensure they get the benefits from the therapy.
OncLive
cancer
oncology
Рекомендации по теме
0:04:12
Optimal ADT for Patients With Prostate Cancer and CV History
0:01:53
Dr. Nguyen on the Optimal Duration of ADT in High-Risk Prostate Cancer
0:36:43
What every patient should know about ADT (hormone) therapy
0:04:05
ADT and Its Consequences in the Treatment of Prostate Cancer
0:50:36
What they don't tell you about Androgen Deprivation Therapy (ADT, hormone therapy)
0:31:24
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
0:45:31
Advances in ADT: A Guide for Urologists and APPs
0:19:56
Recognizing and Managing Side Effects of Androgen Deprivation Therapy (ADT)
0:45:40
ESMO24# Prostate Cancer Highlights | Reaction from China
0:05:30
Zuclomiphene citrate: overcoming the estrogenic side effects of ADT in mCRPC patients
0:08:59
Role of ADT with Radiation
0:59:08
Advances in ADT: A Guide for Urologists and APPs
0:03:43
STARTAR: ADT + apalutamide + RT + docetaxel for PSA-recurrent prostate cancer following RP
0:11:48
Localized Prostate Cancer: Androgen Deprivation Therapy (ADT) - 2021 Prostate Cancer Conference
0:18:55
ADT-Resistant Metastatic Prostate Cancer
0:05:59
Challenges Associated With ADT for Prostate Cancer
0:11:36
New Study Shows The Impact of Diet on Prostate Cancer | Mark Scholz, MD | PCRI
0:04:43
ADT as Treatment in Metastatic Prostate Cancer
0:44:10
Advances in ADT Part II: A Guide for Urologists
0:40:09
ADT as Foundational Therapy: Consistent T Suppression, Goals, Monitoring, and Delaying Time to CRPC
0:12:11
Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer
0:22:00
Debate: Prostate Cancer Patients Should/Should Not Get Chemo and ADT as a Standard of Care
0:00:17
Ideal Placement for Motion Sensors | ADT
0:15:49
ADT Resistant Non-Metastatic Prostate Cancer (nmCRPC) - 2021 Prostate Cancer Patient Conference